NASDAQ · AMGN

Amgen Inc.

$376.04 +$4.54 (+1.22%) 1D After hours
Session Pulse After hours 1 mentions on Tue · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →
Charting by TradingView

Key Metrics

$200.50B
Market cap
25.71×
P/E · TTM
$37.22B
Revenue · TTM
$7.80B
Net income
EPS · TTM $14.42
Dividend yield 2.6%
Free cash flow $8.60B
Beta · 1Y 0.45
EBITDA · TTM $15.46B
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 4
    The stock moved +8.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$200.50B
Enterprise value$245.79B
Shares outstanding539.7M
52-wk range$269.77 – $391.29
Avg volume · 20D2.7M
Net cash −$45.29B
Book value / share$16.99
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Amgen Inc.
IPO dateJun 17, 1983
Employees31500

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E25.71
P/S5.39
P/FCF23.32
EV/EBITDA15.89
EV/Sales6.60
Graham №$74.23

Profitability

Gross —
Operating 28.4%
Net 21.0%
FCF 23.1%
ROE / ROIC 103.5% · 16.7%

Financial Health

Current ratio1.26
Quick ratio1.01
Debt / equity6.24
Debt / EBITDA 3.71
Net cash −$45.29B
Working capital$6.52B

Cash Flow · TTM

Operating CF $10.76B
Capex −$2.16B
Free cash flow $8.60B
Buybacks —
Dividends paid $5.20B
Shareholder yield 2.6%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

$74.23 vs $376.04
Trades 5.1× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings